Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/204325
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Muñoz Vendrell, Albert | - |
dc.contributor.author | Campoy, Sergio | - |
dc.contributor.author | Caronna, Edoardo | - |
dc.contributor.author | Alpuente, Alicia | - |
dc.contributor.author | Torres Ferrus, Marta | - |
dc.contributor.author | Nieves Castellanos, Candela | - |
dc.contributor.author | Olivier, Marina | - |
dc.contributor.author | Campdelacreu, Jaume | - |
dc.contributor.author | Prat, Joan | - |
dc.contributor.author | Camiña Muñiz, Javier | - |
dc.contributor.author | Molina Martínez, Francisco José | - |
dc.contributor.author | Mínguez Olaondo, Ane | - |
dc.contributor.author | Ruibal Salgado, Marta | - |
dc.contributor.author | Santos Lasaosa, Sonia | - |
dc.contributor.author | Navarro Pérez, María Pilar | - |
dc.contributor.author | Morollón, Noemí | - |
dc.contributor.author | López Bravo, Alba | - |
dc.contributor.author | Cano Sánchez, Luis Miguel | - |
dc.contributor.author | García Sánchez, Sonia María | - |
dc.contributor.author | García Ull, Jésica | - |
dc.contributor.author | Rubio Flores, Laura | - |
dc.contributor.author | González Martínez, Alicia | - |
dc.contributor.author | Quintas, Sonia | - |
dc.contributor.author | Echavarría Íñiguez, Ana | - |
dc.contributor.author | Gil Luque, Sendoa | - |
dc.contributor.author | Castro Sánchez, María Victoria | - |
dc.contributor.author | Adell Ortega, Vanesa | - |
dc.contributor.author | García Alhama, Jessica | - |
dc.contributor.author | Berrocal Izquierdo, Nuria | - |
dc.contributor.author | Belvís, Robert | - |
dc.contributor.author | Díaz Insa, Samuel | - |
dc.contributor.author | Pozo Rosich, Patricia | - |
dc.contributor.author | Huerta Villanueva, Mariano | - |
dc.date.accessioned | 2023-12-11T10:22:26Z | - |
dc.date.available | 2023-12-11T10:22:26Z | - |
dc.date.issued | 2023-06-02 | - |
dc.identifier.issn | 1129-2377 | - |
dc.identifier.uri | http://hdl.handle.net/2445/204325 | - |
dc.description.abstract | Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Science and Business Media LLC | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s10194-023-01585-2 | - |
dc.relation.ispartof | The Journal of Headache and Pain, 2023, vol. 24, num. 1 | - |
dc.relation.uri | https://doi.org/10.1186/s10194-023-01585-2 | - |
dc.rights | cc by (c) Muñoz Vendrell, Albert et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.classification | Migranya | - |
dc.subject.other | Monoclonal antibodies | - |
dc.subject.other | Migraine | - |
dc.title | Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-04T12:39:01Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37268904 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s10194-023-01585-2.pdf | 1.67 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License